CMV Management in Kidney Transplant Recipients

Risk Stratification & Screening

Pre‑transplant CMV IgG serology must be obtained for both donor and recipient to assign risk; a donor‑positive/recipient‑negative (D⁺/R⁻) pairing confers the highest risk for CMV disease. 1
Recipients classified as low‑risk (donor‑negative/recipient‑negative, D⁻/R⁻) do not require routine post‑transplant CMV monitoring. 2, 3

All at‑risk kidney transplant recipients (i.e., any combination except D⁻/R⁻) require monthly quantitative CMV viral load testing for the first 12 months after transplantation, regardless of whether universal prophylaxis or a pre‑emptive strategy is used. 2, 4
The preferred laboratory method for detecting CMV viremia is a quantitative CMV DNA PCR assay; the same assay platform must be used consistently throughout follow‑up to allow reliable trend interpretation. 4
CMV active infection is defined by the detection of viral replication in blood (PCR, antigenemia, culture, or histopathology) irrespective of symptoms. 1, 3
CMV disease requires both documented viremia and attributable clinical manifestations and is categorized as either CMV syndrome or tissue‑invasive disease. 1, 3

Probable CMV syndrome is diagnosed when any of the following are present together with detectable CMV in blood: fever > 38 °C for ≥2 days, new or worsening malaise, leukopenia, ≥5 % atypical lymphocytes, or hepatic transaminases ≥2 × upper limit of normal (in non‑liver transplant recipients). 2, 1
Definite CMV syndrome requires all of the above clinical findings with no alternative explanation. 2

Probable tissue‑invasive disease is identified by organ‑specific symptoms plus CMV detection in blood and/or the affected tissue by PCR or antigenemia. 2, 1
Definite tissue‑invasive disease mandates demonstration of CMV in the involved tissue by culture, immunohistochemistry, or in‑situ hybridization. 2, 1
Typical tissue‑invasive manifestations include:
- Pneumonia – respiratory symptoms with CMV detected in blood or bronchoalveolar lavage (probable) or in lung tissue (definite). 2, 1
- Gastrointestinal disease – GI symptoms with endoscopic lesions and CMV in blood/biopsy (probable) or in GI tissue (definite). 2, 1
- Hepatitis – elevated bilirubin or transaminases with CMV in blood (probable) or liver tissue (definite). 2
- CMV retinitis – requires ophthalmologic confirmation of characteristic lesions (definite only). 2, 4

Acute rejection must be ruled out before attributing allograft dysfunction to CMV disease, especially when the kidney shows rising creatinine. 2, 4
Coinfection with other pathogens occurs in 53 % of CMV disease cases and should be documented because it influences therapeutic decisions. 2

Two primary approaches are endorsed: universal prophylaxis (antiviral given to all at‑risk patients) and pre‑emptive therapy (antiviral initiated only after detection of viremia). 3, 5

For patients who develop CMV disease despite prophylaxis or who fail to respond to therapy, genotypic resistance testing for UL97 and UL54 mutations should be performed. 4
Phenotypic resistance testing may be considered in complex cases where genotypic results are inconclusive. 4

Approximately 55 % of CMV disease episodes occur within the first three months after transplantation; ongoing surveillance through the first year captures late‑onset disease, especially when prophylaxis has delayed early onset. 2

The American Society of Transplantation recommends diagnosing CMV disease in kidney transplant recipients using a two-tiered approach: detect CMV viremia via quantitative PCR or antigenemia assay, combined with specific clinical manifestations that define either CMV syndrome or tissue-invasive disease 6, 7
CMV active infection is defined as viral replication detected by culture, nucleic acid-based assays, antigenemia studies, or histopathologic evidence, regardless of symptoms, as stated by the American Society of Transplantation 8, 9
CMV disease is defined as evidence of CMV infection plus attributable clinical symptoms, subdivided into CMV syndrome or tissue-invasive disease, according to the American Society of Transplantation 8, 9

Probable CMV syndrome requires one or more clinical/laboratory findings, including fever, malaise, leukopenia, atypical lymphocytes, thrombocytopenia, or elevated hepatic transaminases, plus evidence of CMV in blood, as recommended by the American Society of Transplantation 6, 7, 8, 10
Definite CMV syndrome requires all clinical/laboratory findings as above, plus no other identifiable cause of symptoms, as stated by the American Society of Transplantation 6, 7
Probable tissue-invasive CMV disease, such as CMV pneumonia, requires pulmonary symptoms/signs without other documented cause, plus CMV detected in blood and/or bronchoalveolar lavage, according to the American Society of Transplantation 6, 7
Definite tissue-invasive CMV disease requires detection of CMV in affected tissue by culture, immunohistochemistry, or in situ hybridization, as recommended by the American Society of Transplantation 6, 7

The American Society of Transplantation recommends quantitative molecular assay (viral load test) as the preferred method for CMV monitoring, with sensitivity 82-100% and specificity 86-100% for active CMV infection 11, 12
Monthly monitoring for the first year post-transplant is recommended for all at-risk patients, except CMV donor-negative/recipient-negative combinations, as stated by the American Society of Transplantation 6, 7, 11

Acute rejection must be excluded as the cause of clinical symptoms before diagnosing CMV disease, especially if the affected organ is the allograft, as recommended by the American Society of Transplantation 6, 7, 10
Superinfection or coinfection with other pathogens may occur and should be documented, according to the American Society of Transplantation 6, 7
CMV detection does not equal CMV disease, and clinical correlation is essential, as stated by the American Society of Transplantation 11